|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: NO POSITION @ $2.67
Signal Strength: MEDIUM
Indicator can be used in isolation but is strengthened by additional indicator confirmation. Indicator can be applied to the short or medium term timeframe and is able to highlight a potential change in price direction. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Opthea (ASX:OPT)No bar reversal is present for Opthea. Over the last 12 months there have been 6 occurrences of no bar reversals giving a signal probability of 2.3%.
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|CII Ci Resources||1.34||16.1||7,170||0||NEUTRAL|
|BFC Beston Global Food||0.09||10||383,135||0||NEUTRAL|
|HFR Highfield Resources||0.67||9||22,865||0||NEUTRAL|
|LYC Lynas Corporation||2.58||8.9||9,724,310||0||NEUTRAL|
|MLX Metals X||0.11||8.2||3,754,499||0||NEUTRAL|
|BVS Bravura Solutions||5.36||8.1||3,114,316||0||NEUTRAL|
|PTM Platinum Asset Management||4.55||7.6||1,696,244||0||NEUTRAL|
|MGX Mount Gibson Iron||0.91||7.1||3,615,391||0||NEUTRAL|